Alix E Seif

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. doi request reprint Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis
    Alix E Seif
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Cancer Genet 204:227-44. 2011
  2. doi request reprint Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature
    Alix E Seif
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Pediatr Hematol Oncol 32:e349-52. 2010
  3. doi request reprint Secondary adrenal insufficiency in an infant after intrathecal triple chemotherapy
    Alix E Seif
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 55:386-9. 2010
  4. doi request reprint Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009
    Brian T Fisher
    Division of Infectious Diseases, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:68-73. 2014
  5. pmc Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States
    Marko Kavcic
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Cancer 119:1916-23. 2013
  6. pmc Establishment of an 11-Year Cohort of 8733 Pediatric Patients Hospitalized at United States Free-standing Children's Hospitals With De Novo Acute Lymphoblastic Leukemia From Health Care Administrative Data
    Brian T Fisher
    Division of Infectious Diseases Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia Department of Pediatrics Center for Clinical Epidemiology and Biostatistics, the Perelman School of Medicine at the University of Pennsylvania Division of Oncology, The Children s Hospital of Philadelphia Department of Biostatistics and Epidemiology, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
    Med Care 52:e1-6. 2014
  7. doi request reprint Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
    David T Teachey
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Blood 121:5154-7. 2013
  8. doi request reprint Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States
    Marko Kavcic
    Division of Oncology, Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia, and Department of Pediatrics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Pediatr 162:1252-8, 1258.e1. 2013
  9. pmc Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease
    Valerie I Brown
    Division of Oncology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA, 19104, USA
    Immunol Res 42:84-105. 2008
  10. pmc Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling
    David M Barrett
    Department of Pediatrics, Division of Oncology, Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Blood 118:e112-7. 2011

Collaborators

Detail Information

Publications19

  1. doi request reprint Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis
    Alix E Seif
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Cancer Genet 204:227-44. 2011
    ....
  2. doi request reprint Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature
    Alix E Seif
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Pediatr Hematol Oncol 32:e349-52. 2010
    ..Combined with other pediatric reports, our experience supports the efficacy of ITlipAC in pediatric and infant leukemic meningitis...
  3. doi request reprint Secondary adrenal insufficiency in an infant after intrathecal triple chemotherapy
    Alix E Seif
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 55:386-9. 2010
    ..As multiple pediatric leukemia protocols incorporate ITT, particularly in infants, we feel that ITT should be considered as a potential source of adrenal axis suppression...
  4. doi request reprint Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009
    Brian T Fisher
    Division of Infectious Diseases, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:68-73. 2014
    ....
  5. pmc Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States
    Marko Kavcic
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Cancer 119:1916-23. 2013
    ..Moreover, these trials likely underreport the clinical toxicities experienced by patients...
  6. pmc Establishment of an 11-Year Cohort of 8733 Pediatric Patients Hospitalized at United States Free-standing Children's Hospitals With De Novo Acute Lymphoblastic Leukemia From Health Care Administrative Data
    Brian T Fisher
    Division of Infectious Diseases Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia Department of Pediatrics Center for Clinical Epidemiology and Biostatistics, the Perelman School of Medicine at the University of Pennsylvania Division of Oncology, The Children s Hospital of Philadelphia Department of Biostatistics and Epidemiology, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
    Med Care 52:e1-6. 2014
    ..Despite cooperative group therapeutic trials, there remains a paucity of large cohort data on which to conduct epidemiology and comparative effectiveness research studies...
  7. doi request reprint Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
    David T Teachey
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Blood 121:5154-7. 2013
    ..This trial was registered at www.clinicaltrials.gov as #NCT00103285. ..
  8. doi request reprint Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States
    Marko Kavcic
    Division of Oncology, Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia, and Department of Pediatrics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Pediatr 162:1252-8, 1258.e1. 2013
    ..To describe the pharmacoepidemiology of rituximab use in children and to estimate the frequency of infectious events within a 1-year period after rituximab exposure...
  9. pmc Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease
    Valerie I Brown
    Division of Oncology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA, 19104, USA
    Immunol Res 42:84-105. 2008
    ....
  10. pmc Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling
    David M Barrett
    Department of Pediatrics, Division of Oncology, Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Blood 118:e112-7. 2011
    ....
  11. doi request reprint Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia
    Brian T Fisher
    Division of Infectious Diseases, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA fi
    Leuk Lymphoma 54:1633-9. 2013
    ..Antibiotic use for children with newly diagnosed ALL varies widely across children's hospitals and is not explained by demographics or illness severity...
  12. pmc Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
    Shannon L Maude
    Division of Oncology, The Children s Hospital of Philadelphia, PA, USA
    Blood 120:3510-8. 2012
    ....
  13. pmc Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)
    David T Teachey
    Children s Hospital of Philadelphia, University of Pennsylvania, 19104, USA
    Br J Haematol 148:205-16. 2010
    ..This review describes the clinical and laboratory manifestations found in ALPS patients, as well as the molecular basis for the disease and new advances in treatment...
  14. pmc Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses
    Alix E Seif
    Children s Hospital of Philadelphia, PA, USA
    Blood 114:2459-66. 2009
    ..To our knowledge, this is the first demonstration that CpG ODN induce a durable remission and ongoing immune-mediated protection in ALL, suggesting this treatment may have clinical utility in patients with minimal residual disease...
  15. pmc Targeting Notch signaling in autoimmune and lymphoproliferative disease
    David T Teachey
    Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine 19104, USA
    Blood 111:705-14. 2008
    ..Inhibiting the Notch signaling pathway may thus present an effective, novel, and well-tolerated treatment for autoimmune and lymphoproliferative diseases...
  16. doi request reprint Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma
    Leah A Commander
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Br J Haematol 150:345-51. 2010
    ..Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored...
  17. doi request reprint Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study
    Alix E Seif
    Division of Hematology, Department of Pediatrics, Children s Hospital of Philadelphia, PA 19104, USA
    Blood 115:2142-5. 2010
    ..This is the largest published series describing children with ES and documents a high rate of ALPS among pediatric ES patients. These data suggest that children with ES should be screened for ALPS with DNTs...
  18. pmc mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
    David T Teachey
    Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, PA 19104, USA
    Blood 112:2020-3. 2008
    ..We found methotrexate and MTIs are an effective and potentially synergistic combination in ALL...
  19. doi request reprint Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database
    Dana M Walker
    Division of Oncology, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 60:616-20. 2013
    ....